Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients

Raffaella Calati, Concetta Crisafulli, Martina Balestri, Alessandro Serretti, Edoardo Spina, Marco Calabrò, Antonina Sidoti, Diego Albani, Isabelle Massat, Peter Höfer, Daniela Amital, Alzbeta Juven-Wetzler, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Julien Mendlewicz

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Treatment resistant depression (TRD) is a significant clinical and public health problem. Among others, neuroplasticity and inflammatory pathways seem to play a crucial role in the pathomechanisms of antidepressant efficacy.The primary aim of this study was to investigate whether a set of single nucleotide polymorphisms (SNPs) within two genes implicated in neuroplasticity and inflammatory processes (the mitogen activated protein kinase 1, MAPK1 (rs3810608, rs6928, rs13515 and rs8136867), and the cyclic AMP responsive element binding protein 1, CREB1 (rs889895, rs6740584, rs2551922 and rs2254137)) was associated with antidepressant treatment resistance (according to two different definitions), in 285 Major Depressive Disorder (MDD) patients. As secondary aims, we investigated the genetic modulation of the same SNPs on response, remission and other clinical features both in MDD patients and in a larger sample including 82 Bipolar Disorder (BD) patients as well. All patients were screened in the context of a European multicenter project.No association between both the investigated genes and treatment resistance and response was found in MDD patients. However, considering remission, higher rates of CREB1 rs889895 GG genotype were reported in MDD patients. Moreover, MAPK1 rs8136867 AG genotype was found to be associated with remission in the whole sample (MDD and BD).Present results suggest that some genetic polymorphisms in both CREB1 and MAPK1 could be associated with treatment remission. Although further research is needed to draw more definitive conclusions, such results are intriguing since suggest a potential role of two genes implicated in neuroplasticity and inflammatory processes in symptom remission after antidepressant treatment.

Original languageEnglish
Pages (from-to)271-278
Number of pages8
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume44
DOIs
Publication statusPublished - Jul 1 2013

Fingerprint

Mood Disorders
Major Depressive Disorder
Neuronal Plasticity
Antidepressive Agents
Bipolar Disorder
Single Nucleotide Polymorphism
Therapeutics
Genotype
Genes
Treatment-Resistant Depressive Disorder
Mitogen-Activated Protein Kinase 1
Genetic Polymorphisms
Cyclic AMP
Carrier Proteins
Public Health
Research

Keywords

  • CREB1
  • Major depressive disorder
  • MAPK1
  • Remission
  • Response
  • Treatment resistance

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. / Calati, Raffaella; Crisafulli, Concetta; Balestri, Martina; Serretti, Alessandro; Spina, Edoardo; Calabrò, Marco; Sidoti, Antonina; Albani, Diego; Massat, Isabelle; Höfer, Peter; Amital, Daniela; Juven-Wetzler, Alzbeta; Kasper, Siegfried; Zohar, Joseph; Souery, Daniel; Montgomery, Stuart; Mendlewicz, Julien.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 44, 01.07.2013, p. 271-278.

Research output: Contribution to journalArticle

Calati, R, Crisafulli, C, Balestri, M, Serretti, A, Spina, E, Calabrò, M, Sidoti, A, Albani, D, Massat, I, Höfer, P, Amital, D, Juven-Wetzler, A, Kasper, S, Zohar, J, Souery, D, Montgomery, S & Mendlewicz, J 2013, 'Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients', Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 44, pp. 271-278. https://doi.org/10.1016/j.pnpbp.2013.03.005
Calati, Raffaella ; Crisafulli, Concetta ; Balestri, Martina ; Serretti, Alessandro ; Spina, Edoardo ; Calabrò, Marco ; Sidoti, Antonina ; Albani, Diego ; Massat, Isabelle ; Höfer, Peter ; Amital, Daniela ; Juven-Wetzler, Alzbeta ; Kasper, Siegfried ; Zohar, Joseph ; Souery, Daniel ; Montgomery, Stuart ; Mendlewicz, Julien. / Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2013 ; Vol. 44. pp. 271-278.
@article{6a545f7b709f4ba2964135e6305c76c1,
title = "Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients",
abstract = "Treatment resistant depression (TRD) is a significant clinical and public health problem. Among others, neuroplasticity and inflammatory pathways seem to play a crucial role in the pathomechanisms of antidepressant efficacy.The primary aim of this study was to investigate whether a set of single nucleotide polymorphisms (SNPs) within two genes implicated in neuroplasticity and inflammatory processes (the mitogen activated protein kinase 1, MAPK1 (rs3810608, rs6928, rs13515 and rs8136867), and the cyclic AMP responsive element binding protein 1, CREB1 (rs889895, rs6740584, rs2551922 and rs2254137)) was associated with antidepressant treatment resistance (according to two different definitions), in 285 Major Depressive Disorder (MDD) patients. As secondary aims, we investigated the genetic modulation of the same SNPs on response, remission and other clinical features both in MDD patients and in a larger sample including 82 Bipolar Disorder (BD) patients as well. All patients were screened in the context of a European multicenter project.No association between both the investigated genes and treatment resistance and response was found in MDD patients. However, considering remission, higher rates of CREB1 rs889895 GG genotype were reported in MDD patients. Moreover, MAPK1 rs8136867 AG genotype was found to be associated with remission in the whole sample (MDD and BD).Present results suggest that some genetic polymorphisms in both CREB1 and MAPK1 could be associated with treatment remission. Although further research is needed to draw more definitive conclusions, such results are intriguing since suggest a potential role of two genes implicated in neuroplasticity and inflammatory processes in symptom remission after antidepressant treatment.",
keywords = "CREB1, Major depressive disorder, MAPK1, Remission, Response, Treatment resistance",
author = "Raffaella Calati and Concetta Crisafulli and Martina Balestri and Alessandro Serretti and Edoardo Spina and Marco Calabr{\`o} and Antonina Sidoti and Diego Albani and Isabelle Massat and Peter H{\"o}fer and Daniela Amital and Alzbeta Juven-Wetzler and Siegfried Kasper and Joseph Zohar and Daniel Souery and Stuart Montgomery and Julien Mendlewicz",
year = "2013",
month = "7",
day = "1",
doi = "10.1016/j.pnpbp.2013.03.005",
language = "English",
volume = "44",
pages = "271--278",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients

AU - Calati, Raffaella

AU - Crisafulli, Concetta

AU - Balestri, Martina

AU - Serretti, Alessandro

AU - Spina, Edoardo

AU - Calabrò, Marco

AU - Sidoti, Antonina

AU - Albani, Diego

AU - Massat, Isabelle

AU - Höfer, Peter

AU - Amital, Daniela

AU - Juven-Wetzler, Alzbeta

AU - Kasper, Siegfried

AU - Zohar, Joseph

AU - Souery, Daniel

AU - Montgomery, Stuart

AU - Mendlewicz, Julien

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Treatment resistant depression (TRD) is a significant clinical and public health problem. Among others, neuroplasticity and inflammatory pathways seem to play a crucial role in the pathomechanisms of antidepressant efficacy.The primary aim of this study was to investigate whether a set of single nucleotide polymorphisms (SNPs) within two genes implicated in neuroplasticity and inflammatory processes (the mitogen activated protein kinase 1, MAPK1 (rs3810608, rs6928, rs13515 and rs8136867), and the cyclic AMP responsive element binding protein 1, CREB1 (rs889895, rs6740584, rs2551922 and rs2254137)) was associated with antidepressant treatment resistance (according to two different definitions), in 285 Major Depressive Disorder (MDD) patients. As secondary aims, we investigated the genetic modulation of the same SNPs on response, remission and other clinical features both in MDD patients and in a larger sample including 82 Bipolar Disorder (BD) patients as well. All patients were screened in the context of a European multicenter project.No association between both the investigated genes and treatment resistance and response was found in MDD patients. However, considering remission, higher rates of CREB1 rs889895 GG genotype were reported in MDD patients. Moreover, MAPK1 rs8136867 AG genotype was found to be associated with remission in the whole sample (MDD and BD).Present results suggest that some genetic polymorphisms in both CREB1 and MAPK1 could be associated with treatment remission. Although further research is needed to draw more definitive conclusions, such results are intriguing since suggest a potential role of two genes implicated in neuroplasticity and inflammatory processes in symptom remission after antidepressant treatment.

AB - Treatment resistant depression (TRD) is a significant clinical and public health problem. Among others, neuroplasticity and inflammatory pathways seem to play a crucial role in the pathomechanisms of antidepressant efficacy.The primary aim of this study was to investigate whether a set of single nucleotide polymorphisms (SNPs) within two genes implicated in neuroplasticity and inflammatory processes (the mitogen activated protein kinase 1, MAPK1 (rs3810608, rs6928, rs13515 and rs8136867), and the cyclic AMP responsive element binding protein 1, CREB1 (rs889895, rs6740584, rs2551922 and rs2254137)) was associated with antidepressant treatment resistance (according to two different definitions), in 285 Major Depressive Disorder (MDD) patients. As secondary aims, we investigated the genetic modulation of the same SNPs on response, remission and other clinical features both in MDD patients and in a larger sample including 82 Bipolar Disorder (BD) patients as well. All patients were screened in the context of a European multicenter project.No association between both the investigated genes and treatment resistance and response was found in MDD patients. However, considering remission, higher rates of CREB1 rs889895 GG genotype were reported in MDD patients. Moreover, MAPK1 rs8136867 AG genotype was found to be associated with remission in the whole sample (MDD and BD).Present results suggest that some genetic polymorphisms in both CREB1 and MAPK1 could be associated with treatment remission. Although further research is needed to draw more definitive conclusions, such results are intriguing since suggest a potential role of two genes implicated in neuroplasticity and inflammatory processes in symptom remission after antidepressant treatment.

KW - CREB1

KW - Major depressive disorder

KW - MAPK1

KW - Remission

KW - Response

KW - Treatment resistance

UR - http://www.scopus.com/inward/record.url?scp=84876335561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876335561&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2013.03.005

DO - 10.1016/j.pnpbp.2013.03.005

M3 - Article

C2 - 23537502

AN - SCOPUS:84876335561

VL - 44

SP - 271

EP - 278

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

ER -